Blood Analytes as Biomarkers of Mechanisms Involved in Alzheimer’s Disease Progression

• Published in: International journal of molecular sciences 2022-11, Vol.23 (21), p.13289
• Main Authors: Baldini, Andrea, Greco, Alberto, Lomi, Mirko, Giannelli, Roberta, Canale, Paola, Diana, Andrea, Dolciotti, Cristina, Del Carratore, Renata, Bongioanni, Paolo
• Format: Article
• Language: English
• Subjects: Alzheimer's disease; Biomarkers; Blood; blood neurodegenerative biomarkers; Cholesterol; Cognitive ability; Datasets; Dementia; Dementia disorders; Ferritin; generalized linear mixed-effects models; Laboratories; Machine learning; Mathematical models; Metabolism; Neurodegeneration; pathways; Patients; Statistical analysis; Statistical models; Therapeutic targets
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232113289

Alzheimer’s disease (AD) is the leading cause of dementia, but the pathogenetic factors are not yet well known, and the relationships between brain and systemic biochemical derangements and disease onset and progression are unclear. We aim to focus on blood biomarkers for an accurate prognosis of the disease. We used a dataset characterized by longitudinal findings collected over the past 10 years from 90 AD patients. The dataset included 277 observations (both clinical and biochemical ones, encompassing blood analytes encompassing routine profiles for different organs, together with immunoinflammatory and oxidative markers). Subjects were grouped into four severity classes according to the Clinical Dementia Rating (CDR) Scale: mild (CDR = 0.5 and CDR = 1), moderate (CDR = 2), severe (CDR = 3) and very severe (CDR = 4 and CDR = 5). Statistical models were used for the identification of potential blood markers of AD progression. Moreover, we employed the Pathfinder tool of the Reactome database to investigate the biological pathways in which the analytes of interest could be involved. Statistical results reveal an inverse significant relation between four analytes (high-density cholesterol, total cholesterol, iron and ferritin) with AD severity. In addition, the Reactome database suggests that such analytes could be involved in pathways that are altered in AD progression. Indeed, the identified blood markers include molecules that reflect the heterogeneous pathogenetic mechanisms of AD. The combination of such blood analytes might be an early indicator of AD progression and constitute useful therapeutic targets.